|
cell proliferation |
Increase in the number of cells as a result of cell division |
|
chemotherapy |
The use of chemical agents in the treatment or control of disease or mental disorders |
|
clinical trials |
Medical research studies conducted on human subjects to answer scientific questions and to find better ways to prevent, detect or treat diseases |
|
efficacy |
The ability of a drug to control or cure an illness or disease |
|
FDA |
Food and Drug Administration |
|
formulation |
Incorporation of a drug into a relevant delivery vehicle, such as a gel |
|
GMP |
Good Manufacturing Process |
|
intravenous (IV) |
Situated within, performed within, occurring within, or administered by entering a vein - injection of a drug into the bloodstream through a vein |
|
intra-cavitary (IC) |
Situated or occurring within a body cavity (i.e. treatment characterized by the insertion of substances in a cavity) |
|
IND |
Investigational new drug |
|
kinase |
An enzyme that catalyzes the transfer of phosphate groups from a high-energy phosphate-containing molecule (as ATP or ADP) to a substrate |
|
malignant |
Cancerous - of unfavorable prognosis |
|
melanocytes |
An epidermal cell that produces melanin |
|
metastases, metastasise |
Transfer of a disease-producing agency (e.g. cancer cells) from an original site of disease to another part of the body with development of a similar lesion in a new location |
|
mutation |
A relatively permanent change in hereditary material (gene) involving a physical change in chromosome relations |
|
pathway |
A system of proteins that work together |
|
pharmacokinetics |
The study of the bodily absorption, distribution, metabolism and excretion of drugs |
|
pharmacology |
Evaluation of the activity of the drug in various cell systems and animal models of the disease |
|
phase I |
Clinical trial designed to determine the safety and appropriate dose |
|
phase II |
Clinical trial designed to measure the safety and efficacy |
|
phase III |
Clinical trial designed to test new treatment and measure efficacy as well as safety as compared to the standard of care |
|
progression |
A trend or shift toward a high, more severe state - increase of tumour size (opposite of regression) |
|
receptor |
A chemical group or molecule (as a protein) on the cell surface or in the cell interior that has an affinity for a specific chemical group, molecule, or virus |
|
regimen |
A systematic plan designed to improve and maintain the health of a patient |
|
regression |
A trend or shift toward a lower, less severe or less perfect state - reduction in the size of tumour (opposite of progression) |
|
therapeutic |
Of or relating to the treatment of disease or disorders by remedial agents or methods |
|
therapy (therapies) |
Treatment(s) |
|
toxicity |
The quality, state, or relative degree of being toxic or poisonous |
|
toxicology |
Evaluation of the safety profile of a drug |
|
tumour |
An abnormal benign or malignant mass of tissue that is not inflammatory, arises without obvious cause from cells of preexistent tissue, and possesses no physiological function |